Posted on

Plasma-derived Coagulation Factor VIII for prophylaxis/prevention of bleeding in the pediatric population with hemophilia A

General Track – Cycle 2 | Drugs

HTA Council Recommendation (as of 29 April 2025)

The HTA Council recommends the government financing of Plasma-derived Coagulation Factor VIII for prophylaxis/prevention of bleeding in the pediatric population with hemophilia A. (See below for more details)

Relevant Information

  • Dosage Strengths:
    • 250 IU/10 mL (25 IU/mL)
    • 250 IU/5mL (50IU/mL); 500 IU/10mL (50 IU/mL)
    • 500 IU/5ml (100 IU/mL); 1000 IU/10mL (100 IU/mL)
  • Dosage Form: Powder solution for IV
  • Status: With Final HTA Council Recommendation
  • Topic Assignment: Internal Assessment
  • Policy Question: Should Plasma-derived Coagulation Factor VIII for prophylaxis/prevention of bleeding in the pediatric population with hemophilia A be funded by the government?
  • Secretary of Health Decision: pending

Evidence and Relevant Documents

Assessments Page